113 related articles for article (PubMed ID: 30878539)
1. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis.
Paciotti S; Sepe FN; Eusebi P; Farotti L; Cataldi S; Gatticchi L; Parnetti L
Clin Chim Acta; 2019 Jul; 494():74-78. PubMed ID: 30878539
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.
Dakterzada F; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Piñol-Ripoll G
Front Aging Neurosci; 2021; 13():604119. PubMed ID: 33746733
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
7. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
[TBL] [Abstract][Full Text] [Related]
8. Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo G; Cataldi S; Paciotti S; Paolini Paoletti F; Chiasserini D; Parnetti L
Alzheimers Res Ther; 2020 Sep; 12(1):121. PubMed ID: 32993776
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
[TBL] [Abstract][Full Text] [Related]
17. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
18. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
